They are developing innovative therapeutic strategies to treat HER2 positive tumours and to identify mechanisms of resistance to current treatments. Working on the characterisation of the role of premature senescence in the progression and treatment of breast cancer, and the study of the implications of the immune system for the progression of cancer.

Among other strategic objectives is the evaluation of the activity of innovative therapeutic strategies in our sets of xenografts deriving from breast and pancreatic cancer patients. And the continued development of a research programme into pancreatic cancer in close collaboration with the clinical research programme run by the Vall d'Hebron Institute of Oncology (VHIO), led by Josep Tabernero. 

Visit the research group’s page